Evidence map›Paper›PMID 37579656›Full record

ArticleThe American journal of cardiology2023

Clinical Response to Tumor Necrosis Factor-α Inhibitor Therapy in the Management of Cardiac Sarcoidosis.

Robert Churchill, Daniel Sykora, Matteo Castrichini, Courtney Arment, Elena Myasoedova, Mohamed Elwazir, John Bois, Kathleen Young, Andrew Rosenbaum

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. The role of infliximab in treating refractory cardiac sarcoidosis. Case series and systematic review of literature.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Robert ChurchillMayo Clinic Alix School of Medicine, Mayo Clinic College of eEdicine and Science, Mayo Clinic, Rochester, Minnesota.
Daniel SykoraDepartment of General Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Matteo CastrichiniDepartment of General Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Courtney ArmentDivision of Rheumatology, Department of General Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Elena MyasoedovaDivision of Rheumatology, Department of General Internal Medicine, Mayo Clinic, Rochester, Minnesota; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
Mohamed ElwazirDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
John BoisDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
Kathleen YoungDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
Andrew RosenbaumDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota. Electronic address: Rosenbaum.andrew@mayo.edu.
Mayo Clinic · US

Funding

Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4M
NCATS NIH HHS UL1 TR002377
6 · The paper itself

Abstract

Evidence that tumor necrosis factor-α (TNF-α) inhibitors may benefit patients with cardiac sarcoidosis (CS) is limited to small case series and both imaging and clinical outcomes in this population are not well known. This study aimed to evaluate the disease course of patients with CS treated with either infliximab or adalimumab therapy based on serial

Indexed as

CardiomyopathiesMyocarditisSarcoidosisAdalimumabFluorodeoxyglucose F18HumansInfliximabPositron-Emission TomographyPrednisoneRadiopharmaceuticalsTumor Necrosis Factor-alphaAdalimumabFluorodeoxyglucose F18InfliximabPrednisoneRadiopharmaceuticalsTumor Necrosis Factor-alphacardiac sarcoidosisFDG-PET scanstandard uptake value maximumTNF-α inhibitor

Identifiers

PMID37579656
PMCPMC11406697
OpenAlexW4385785895

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.